Table 3.

Percentage of inhibition of Aβ42 aggregation by Cur or SLCP in comparison to untreated group, *p < 0.05, **p < 0.01, relative to untreated Aβ42

	6-E10 antibodies				OC antibodies				A11 antibody
Duration	24 h		48 h		24 h		48 h		8 h
Treatment Groups	Aβ42+ Cur	Aβ42+ SLCP	Aβ42+ Cur	Aβ42+ SLCP	Aβ42+ Cur	Aβ42+ SLCP	Aβ42+ Cur	Aβ42+ SLCP	Aβ42+ Cur	Aβ42+ SLCP
1 μM	64.54	48.34*	26.25	51.68**	16.99	41.04**	18.95	37.11*	24.20	43.75*
100 nM	71.99	48.44**	31.21	58.69**	21.64	30.59	60.81	36.45*	7.63	48.37**
10 nM	63.96	59.76	18.38	65.70**	27.54	35.15	105.15	33.29*	17.59	53.68**
1 nM	65.05	55.82*	37.34	65.00**	23.07	38.70*	− 73.09	56.82**	22.37	46.74*